Zoledronic acid infusion after hip fracture decreases new fracture rate and mortality

MOspace/Manakin Repository

Breadcrumbs Navigation

Zoledronic acid infusion after hip fracture decreases new fracture rate and mortality

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/7509

[+] show full item record


Title: Zoledronic acid infusion after hip fracture decreases new fracture rate and mortality
Author: Rowland, Kate
Keywords: vitamin supplement
Date: 2009-07
Publisher: Family Physicians Inquiries Network
Citation: Evidence Based Practice 12(7): 01-02.
Abstract: Osteoporosis is estimated to contribute to more than 2 million fractures each year, and about 25% of people who sustain osteoporosis-related fractures will die within a year of the fracture. After a fracture, treatment of osteoporosis with a bisphosphonate can reduce the risk of a subsequent fracture, but compliance with oral bisphosphonates is low. Intravenous (IV) bisphosphonates are a relatively new treatment option for osteoporosis. Zoledronic acid (Reclast) and ibandronate (Boniva IV) are the only IV bisphosphonates currently indicated for the treatment of osteoporosis.
URI: http://hdl.handle.net/10355/7509

This item appears in the following Collection(s)

[+] show full item record